



Correction to: Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma

Lisa May Ling Tachiki^{1,3} · Daniel S. Hippe³ · Karly Williams Silva^{1,3} · Evan Thomas Hall^{1,3} · William McCamy¹ · Dane Fritzsche³ · Andrea Perdue^{1,3} · Julia Majovski^{1,3} · Thomas Pulliam^{2,3} · Daniel A. Goldstein⁴ · Joshua Veatch^{1,3} · Joel Ho^{1,3} · Paul T. Nghiem^{2,3} · John A. Thompson^{1,3} · Shailender Bhatia^{1,3}

Published online: 18 November 2023
© The Author(s) 2023

Correction to:

**Cancer Immunology, Immunotherapy (2023)
72:3839–3850**
<https://doi.org/10.1007/s00262-023-03539-8>

The original version of this article unfortunately contained a mistake. The corrected detail is provided below:

In discussion section, 6th sentence of the 10th paragraph which previously read:

In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit extended duration of treatment with RFD.

Should read:

In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit from extended duration of treatment with RFD.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00262-023-03539-8>.

✉ Lisa May Ling Tachiki
ltachiki@uw.edu

✉ Shailender Bhatia
sbhatia@uw.edu

¹ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA

² Department of Medicine, Division of Dermatology, University of Washington, Seattle, WA, USA

³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA

⁴ Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel